Effects on bone by the light/dark cycle and chronic treatment with melatonin and/or hormone replacement therapy in intact female mice

Journal of Pineal Research

Volumn 53, Issue 4, 2012, Pages 374-384

  Witt Enderby, Paula A ^a   Slater, John P ^a   Johnson, Nakpangi A ^a   Bondi, Corry D ^a   Dodda, Balasunder R ^a   Kotlarczyk, Mary P ^a   Clafshenkel, William P ^a   Sethi, Shalini ^a   Higginbotham, Suzanne ^a   Rutkowski, James L ^b   Gallagher, Katie M ^a   Davis, Vicki L ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b Clarion Research Group   (United States)

Author keywords

bone density; bone morphogenetic proteins; circadian; hormone replacement therapy (HRT); melatonin; menopause; osteoporosis; Per 2; retinal degeneration

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 6; CYCLOPHILIN A; DRINKING WATER; ESTRADIOL; MELATONIN; MESSENGER RNA; OSTEOCALCIN; PER2 PROTEIN; PROGESTERONE; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CIRCADIAN RHYTHM; CLIMACTERIUM; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; LIGHT DARK CYCLE; LONG TERM CARE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; REAL TIME POLYMERASE CHAIN REACTION; RETINA DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRABECULAR BONE; TRANSGENIC MOUSE;

EID: 84867747948     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2012.01007.x     Document Type: Article

References (82)

1. Sanchez-Barcelo EJ, Mediavilla MD, Reiter RJ,. Scientific basis for the potential use of melatonin in bone diseases: osteoporosis and adolescent idiopathic scoliosis. J Osteoporosis 2010; 2010: 830231.
2. Ostrowska Z, Kos-Kudla B, Marek B, et al., Assessment of the relationship between circadian variations of salivary melatonin levels and type I collagen metabolism in postmenopausal obese women. Neuro Endocrinol Lett 2001; 22: 121-127.
3. Sadat-Ali M, Al-Habdan I, Al-Othman A,. Adolescent idiopathic scoliosis. Is low melatonin a cause? Joint Bone Spine 2000; 67: 62-64.
4. Moreau A, Wang DS, Forget S, et al., Melatonin signaling dysfunction in adolescent idiopathic scoliosis. Spine 2004; 29: 1772-1781.
5. Azeddine B, Letellier K, Wang DS, et al., Molecular determinants of melatonin signaling dysfunction in adolescent idiopathic scoliosis. Clin Orthop Relat Res 2007; 462: 45-52.
6. Novakova M, Nevsimalova S, Prihodova I, et al., Alteration of the circadian clock in children with Smith-Magenis syndrome. J Clin Endocrinol Metab 2012; 97: E312-E318.
7. Potocki L, Glaze D, Tan DX, et al., Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet 2000; 37: 428-433.
8. Ostrowska Z, Kos-Kudla B, Marek B, et al., Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul 2003; 37: 163-174.
9. Ostrowska Z, Kos-Kudla B, Nowak M, et al., The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr Regul 2003; 37: 211-224.
10. Machida M, Dubousset J, Imamura Y, et al., Role of melatonin deficiency in the development of scoliosis in pinealectomised chickens. J Bone Joint Surg Br 1995; 77: 134-138.
11. Fjelldal PG, Grotmol S, Kryvi H, et al., Pinealectomy induces malformation of the spine and reduces the mechanical strength of the vertebrae in Atlantic salmon, Salmo salar. J Pineal Res 2004; 36: 132-139.
12. Turgut M, Kaplan S, Turgut AT, et al., Morphological, stereological and radiological changes in pinealectomized chicken cervical vertebrae. J Pineal Res 2005; 39: 392-399.
13. Oyama J, Murai I, Kanazawa K, et al., Bipedal ambulation induces experimental scoliosis in C57BL/6J mice with reduced plasma and pineal melatonin levels. J Pineal Res 2006; 40: 219-224.
14. Kono H, Machida M, Saito M, et al., Mechanism of osteoporosis in adolescent idiopathic scoliosis: experimental scoliosis in pinealectomized chickens. J Pineal Res 2011; 51: 387-393.
15. Egermann M, Gerhardt C, Barth A, et al., Pinealectomy affects bone mineral density and structure - an experimental study in sheep. BMC Musculoskelet Disord 2011; 12: 271.
16. Uebelhart D, Schlemmer A, Johansen JS, et al., Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991; 72: 367-373.
17. Schlemmer A, Hassager C, Jensen SB, et al., Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74: 476-480.
18. Greenspan SL, Dresner-Pollak R, Parker RA, et al., Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 1997; 60: 419-423.
19. Eastell R, Calvo MS, Burritt MF, et al., Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 1992; 74: 487-494.
20. Hardeland R, Madrid JA, Tan DX, et al., Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012; 52: 139-166.
21. Feskanich D, Hankinson SE, Schernhammer ES,. Nightshift work and fracture risk: the Nurses' Health Study. Osteopor Int 2009; 20: 537-542.
22. Kotlarczyk MP, Lassila HC, O'neil CK, et al., Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res 2012; 52: 414-426.
23. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012; 19: 257-271.
24. Guy CT, Webster MA, Schaller M, et al., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992; 89: 10578-10582.
25. Taketo M, Schroeder AC, Mobraaten LE, et al., FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A 1991; 88: 2065-2069.
26. Lockley SW, Skene DJ, Arendt J, et al., Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab 1997; 82: 3763-3770.
27. Dijk DJ, Lockley SW,. Integration of human sleep-wake regulation and circadian rhythmicity. J Appl Physiol 2002; 92: 852-862.
28. Roth JA, Kim BG, Lin WL, et al., Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999; 274: 22041-22047.
29. Zhang L, Su P, Xu C, et al., Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARgamma expression and enhancing Runx2 expression. J Pineal Res 2010; 49: 364-372.
30. Sethi S, Radio NM, Kotlarczyk MP, et al., Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res 2010; 49: 222-238.
31. Park KH, Kang JW, Lee EM, et al., Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J Pineal Res 2011; 51: 187-194.
32. Fu L, Patel MS, Bradley A, et al., The molecular clock mediates leptin-regulated bone formation. Cell 2005; 122: 803-815.
33. Maronde E, Schilling AF, Seitz S, et al., The clock genes Period 2 and Cryptochrome 2 differentially balance bone formation. PLoS ONE 2010; 5: e11527.
34. Jung-Hynes B, Huang W, Reiter RJ, et al., Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-68.
35. Isobe Y, Nishino H,. Signal transmission from the suprachiasmatic nucleus to the pineal gland via the paraventricular nucleus: analysed from arg-vasopressin peptide, rPer2 mRNA and AVP mRNA changes and pineal AA-NAT mRNA after the melatonin injection during light and dark periods. Brain Res 2004; 1013: 204-211.
36. Johnston JD, Tournier BB, Andersson H, et al., Multiple effects of melatonin on rhythmic clock gene expression in the mammalian pars tuberalis. Endocrinology 2006; 147: 959-965.
37. Gery S, Virk RK, Chumakov K, et al., The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007; 26: 7916-7920.
38. Henrard D, Ross SR,. Endogenous mouse mammary tumor virus is expressed in several organs in addition to the lactating mammary gland. J Virol 1988; 62: 3046-3049.
39. Anisimov VN, Alimova IN, Baturin DA, et al., The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer 2003; 103: 300-305.
40. Ireland D,. Analysis of gene expression in bone by quantitative RT-PCR. Methods Mol Med 2003; 80: 433-440.
41. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
42. Lucas RJ, Freedman MS, Lupi D, et al., Identifying the photoreceptive inputs to the mammalian circadian system using transgenic and retinally degenerate mice. Behav Brain Res 2001; 125: 97-102.
43. Provencio I, Wong S, Lederman AB, et al., Visual and circadian responses to light in aged retinally degenerate mice. Vision Res 1994; 34: 1799-1806.
44. Ducy P, Desbois C, Boyce B, et al., Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452.
45. Ducy P, Starbuck M, Priemel M, et al., A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999; 13: 1025-1036.
46. Komori T, Yagi H, Nomura S, et al., Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764.
47. Komori T,. Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab 2003; 21: 193-197.
48. Komori T,. Regulation of bone development and maintenance by Runx2. Front Biosci 2008; 13: 898-903.
49. Chen D, Zhao M, Mundy GR,. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-241.
50. Nakamura A, Dohi Y, Akahane M, et al., Osteocalcin secretion as an early marker of in vitro osteogenic differentiation of rat mesenchymal stem cells. Tissue Eng Part C Methods 2009; 15: 169-180.
51. Isojima Y, Okumura N, Nagai K,. Molecular mechanism of mammalian circadian clock. J Biochem (Tokyo) 2003; 134: 777-784.
52. Moriya T, Hiraishi K, Horie N, et al., Correlative association between circadian expression of mousePer2 gene and the proliferation of the neural stem cells. Neuroscience 2007; 146: 494-498.
53. Gu X, Xing L, Shi G, et al., The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ 2012; 19: 397-405.
54. Ripperger JA, Schmutz I, Albrecht U,. PERsuading nuclear receptors to dance the circadian rhythm. Cell Cycle 2010; 9: 2515-2521.
55. Kennaway DJ, Voultsios A, Varcoe TJ, et al., Melatonin in mice: rhythms, response to light, adrenergic stimulation, and metabolism. Am J Physiol Regul Integr Comp Physiol 2002; 282: R358-R365.
56. Blask DE, Brainard GC, Dauchy RT, et al., Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-11184.
57. Iguichi H, Kato KI, Ibayashi H,. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27-29.
58. Sandyk R, Anastasiadis PG, Anninos PA, et al., Is postmenopausal osteoporosis related to pineal gland functions? Int J Neurosci 1992; 62: 215-225.
59. Vakkuri O, Kivela A, Leppaluoto J, et al., Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol 1996; 135: 188-192.
60. Bellipanni G, Bianchi P, Pierpaoli W, et al., Effects of melatonin in perimenopausal and menopausal women: a -randomized and placebo controlled study. Exp Gerontol 2001; 36: 297-310.
61. Screening for osteoporosis: U.S. Preventative Services Recommendation Statement. Ann Int Med 2011.
62. Witt-Enderby PA, Radio NM, Doctor JS, et al., Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006; 41: 297-305.
63. Radio NM, Doctor JS, Witt-Enderby PA,. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 2006; 40: 332-342.
64. Zaminy A, Ragerdi Kashani I, Barbarestani M, et al., Osteogenic differentiation of rat mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells: melatonin as a differentiation factor. Iran Biomed J 2008; 12: 133-141.
65. Suzuki N, Hattori A,. Melatonin suppresses osteoclastic and osteoblastic activities in the scales of goldfish. J Pineal Res 2002; 33: 253-258.
66. Koyama H, Nakade O, Takada Y, et al., Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 2002; 17: 1219-1229.
67. Seifert-Klauss V, Prior JC,. Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010; 2010: 845180.
68. Srivastava S, Toraldo G, Weitzmann MN, et al., Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001; 276: 8836-8840.
69. Saintier D, Khanine V, Uzan B, et al., Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J Steroid Biochem Mol Biol 2006; 99: 165-173.
70. Robinson LJ, Yaroslavskiy BB, Griswold RD, et al., Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6. Exp Cell Res 2009; 315: 1287-1301.
71. Nakade O, Koyama H, Ariji H, et al., Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 1999; 27: 106-110.
72. Uslu S, Uysal A, Oktem G, et al., Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. Anal Quant Cytol Histol 2007; 29: 317-325.
73. Cutando A, Gãmez-Moreno G, Arana C, et al., Melatonin stimulates osteointegration of dental implants. J Pineal Res 2008; 45: 174-179.
74. Cardinali DP, Ladizesky MG, Boggio V, et al., Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34: 81-87.
75. Ladizesky MG, Boggio V, Albornoz LE, et al., Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J Pineal Res 2003; 34: 143-151.
76. Kos-Kudla B, Ostrowska Z, Marek B, et al., Circadian rhythm of melatonin in postmenopausal asthmatic women with hormone replacement therapy. Neuro Endocrinol Lett 2002; 23: 243-248.
77. Prior JC,. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998; 19: 397-428.
78. Prior JC,. Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 2005; 26: 297-300.
79. Deif M, Fawzy E, Gad H,. Effect of melatonin on some bone turnover markers in ovarectomized rats. Alexandria J Med 2007; 43.
80. Ebeling PR, Atley LM, Guthrie JR, et al., Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996; 81: 3366-3371.
81. Sowers MR, Greendale GA, Bondarenko I, et al., Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteopor Int 2003; 14: 191-197.
82. Sun L, Peng Y, Sharrow AC, et al., FSH directly regulates bone mass. Cell 2006; 125: 247-260.